People with certain types of blood cancers who are eligible for a hematopoietic cell transplant (HCT) may be able to take part in a clinical trial called ALLOHA^TM

In this clinical trial, T cells are first collected from the healthy stem cell transplant donor and sent to the laboratory at TScan. Scientists in the laboratory then modify the T cells to help them recognize a specific protein found in the patient’s blood and cancer cells. Once the T cells are ready, they are frozen and sent back to the hospital so that they can be given to the patient.

Patients will receive their first of two scheduled infusions of TSC-101 approximately 21 days after their HCT and the second infusion about 40 days later. The number of T cells and number of infusions is based on when the patient joins the ALLOHA clinical trial. Patients are closely followed by their doctor and treatment team to help us understand how their cancer has responded and any potential side effects caused by the HCT and T-cell infusion. Patients will be followed as a part of this study for two years after their last T-cell infusion.

Not everyone is able to have one of these T-cell medicines made for them. To see who may potentially be eligible for this study, patients should be receiving reduced intensity conditioning (RIC), a lower dose of chemotherapy or radiation, with their HCT. Additionally, T cells can only recognize the specific target proteins if they are combined with another type of protein called human leukocyte antigen (HLA). Everyone has up to six HLA types and those HLA types can be identified by testing the blood, spit, or by rubbing a piece of cotton along the inside of the cheek. Patients who are HLA-A*02:01-positive and have a donor that is HLA-A*02-negative may be eligible to participate. This mismatch allows the T cells to attack any remaining blood and cancer cells from the patient and therefore potentially reduce the risk of disease relapse. For patients who are considering participation in the ALLOHA trial, please talk to your doctor and care team for more details and to ask any additional questions.